Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions
Kidney Transplant
Interventions
BIOLOGICAL

Abatacept

Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector

PROCEDURE

Standard of Care at US Transplant Centers

Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))

Trial Locations (15)

15213

RECRUITING

University of Pittsburgh Medical Center: Transplantation, Pittsburgh

19104

RECRUITING

University of Pennsylvania Medical Center: Transplantation, Philadelphia

21287

RECRUITING

Johns Hopkins Hospital:Transplantation, Baltimore

22908

RECRUITING

University of Virginia Health System: Transplantation, Charlottesville

27710

RECRUITING

Duke University Medical Center: Transplantation, Durham

35233

RECRUITING

University of Alabama School of Medicine: Transplantation, Birmingham

44195

NOT_YET_RECRUITING

Cleveland Clinic Foundation: Transplantation, Cleveland

53726

NOT_YET_RECRUITING

University of Wisconsin School of Medicine and Public Health: Transplantation, Madison

55905

RECRUITING

Mayo Clinic Rochester: Transplantation, Rochester

63110

RECRUITING

Washington University School of Medicine in St. Louis, St Louis

68198

RECRUITING

University of Nebraska Medical Center: Transplantation, Omaha

90048

RECRUITING

Cedars Sinai Medical Center: Transplantation, Los Angeles

90095

RECRUITING

Ronald Reagan UCLA Medical Center: Transplantation, Los Angeles

06519

RECRUITING

Yale University, School of Medicine: Transplantation, New Haven

02114

RECRUITING

Massachusetts General Hospital: Transplantation, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH